Statin derivatives as therapeutic agents for castration-resistant prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) is an incurable malignancy.
• CRPC cells acquire androgen synthesis capabilities, contributing to treatment resistance.
• Statins like simvastatin inhibit cholesterol biosynthesis, a pathway implicated in prostate cancer progression.

Purpose of the Study:

• To evaluate novel simvastatin derivatives (SVA, AM1, AM2) as potential therapeutics for CRPC.
• To investigate the mechanism of action of these compounds on prostate cancer cells.
• To assess the efficacy of SVA in combination with docetaxel.

Main Methods:

• Testing SVA, AM1, and AM2 on androgen receptor-positive (LNCaP C-81, VCaP) and negative (PC-3, DU145) prostate cancer cell lines.
• Assessing inhibition of cell proliferation, colony formation, and migration.
• Analyzing cell-cycle arrest, apoptosis, androgen receptor signaling, and AKT pathway suppression.
• Evaluating the combined effect of SVA and docetaxel.

Main Results:

• SVA, AM1, and AM2 suppressed tumorigenicity across various prostate cancer cell lines.
• Compounds inhibited proliferation, colony formation, and migration, inducing cell-cycle arrest and apoptosis.
• Mechanisms involved blocking androgen receptor signaling and suppressing the AKT pathway, partly via plasma membrane disruption.
• SVA demonstrated enhanced efficacy when combined with docetaxel.

Conclusions:

• Simvastatin derivatives, particularly SVA, exhibit significant anti-tumorigenic effects on CRPC cells.
• These compounds offer a novel therapeutic strategy by targeting cholesterol biosynthesis and key signaling pathways.
• SVA shows potential as a potent agent for treating castration-resistant prostate cancer, including in combination therapy.